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Abstract
Background The Clinch Token Transfer Test (C3t) is a bi-manual coin transfer task that incorporates cognitive tasks to 
add complexity. This study explored the concurrent and convergent validity of the C3t as a simple, objective assessment of 
impairment that is reflective of disease severity in Huntington’s, that is not reliant on clinical expertise for administration.
Methods One-hundred-and-five participants presenting with pre-manifest (n = 16) or manifest (TFC-Stage-1 n = 39; TFC-
Stage-2 n = 43; TFC-Stage-3 n = 7) Huntington’s disease completed the Unified Huntington’s Disease Rating Scale and the 
C3t at baseline. Of these, thirty-three were followed up after 12 months. Regression was used to estimate baseline individual 
and composite clinical scores (including cognitive, motor, and functional ability) using baseline C3t scores. Correlations 
between C3t and clinical scores were assessed using Spearman’s R and visually inspected in relation to disease severity using 
scatterplots. Effect size over 12 months provided an indication of longitudinal behaviour of the C3t in relation to clinical 
measures.
Results Baseline C3t scores predicted baseline clinical scores to within 9–13% accuracy, being associated with individual 
and composite clinical scores. Changes in C3t scores over 12 months were small ( Ω ≤ 0.15) and mirrored the change in 
clinical scores.
Conclusion The C3t demonstrates promise as a simple, easy to administer, objective outcome measure capable of predicting 
impairment that is reflective of Huntington’s disease severity and offers a viable solution to support remote clinical monitor-
ing. It may also offer utility as a screening tool for recruitment to clinical trials given preliminary indications of association 
with the prognostic index normed for Huntington’s disease.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neu-
rodegenerative disorder that affects 6–13/100,000 in the 
general population [1]. HD is caused by the expansion of a 
cytosine-adenine-guanine (CAG) triplet repeat expansion on 
the Huntingtin gene which leads to pathological symptoms 
once the repeats reach thirty-six or more.
HD is characterized by a complex presentation of motor, 
cognitive, behavioral and functional impairments [2], 
and results in a progressive decline in quality of life over 
15–20 years, ultimately leading to early death. Whilst there 
is currently no recognized cure, substantial progress is being 
made in disease modifying therapeutic interventions, with 
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clinical trials underway [3]. With a real opportunity to slow 
functional decline on the horizon, there is an ever-increasing 
urgency for clinical endpoints that can truly determine the 
influence an intervention has on clinical progression.
At present, clinical trials typically rely on clinician-
reported assessments, with the Unified Huntington’s Dis-
ease Rating Scale (UHDRS) routinely used to assess clinical 
performance and capacity in HD [4]. Individual components 
within the UHDRS facilitate the assessment of motor func-
tion, cognitive function, behavior and functional capacity 
[5, 6]. Whilst assessments of individual domains have fur-
thered understanding of specific aspects of disease progres-
sion [7–9], pre-existing scales are thought to lack sensitivity 
to change and are prone to ceiling affects in pre-manifest and 
early HD [10]. There also remains a distinct lack of validated 
clinical tools capable of assessing upper limb function in HD 
[11].. Such assessments are needed when seeking to under-
stand the real life implications that a movement disorder 
such as HD has on activities of daily living [12]. Further-
more, the current COVID-19 pandemic has highlighted a 
heavy reliance on face to face assessments and a real need 
for robust tools that allow continued remote monitoring of 
symptoms when face to face clinic visits prove challenging. 
Subsequently, there is a recognized need for more granular 
and novel assessments of clinical symptoms, that can be 
performed in the clinic and home environments, to better 
evaluate the influence of novel interventions in HD.
The Moneybox test (herein referred to as the Clinch 
Token Transfer Test (C3t)) is a bi-manual upper limb token 
transfer and manipulation performance assessment, with a 
view to providing an ecologically valid functional assess-
ment underpinned by sound biological rationale for people 
with basal ganglia dysfunction [13]. The C3t has the ben-
efits of being quick to perform and objective in nature, with 
no reliance on clinical expertise to administer and thus real 
potential to deliver a remote solution, for monitoring clini-
cal symptoms at scale. This in turn would increase the depth 
of information available to researchers to help identify and 
understand subtle changes in disease progression.
Early validation work found the C3t to be sensitive to 
HD disease stage and correlated to the components of the 
UHDRS and health related quality of life [13]. An instru-
mented version of the test, involving accelerometer data 
from devices worn on each wrist and the sternum, has also 
successfully discriminated between healthy and HD partici-
pants, with C3t derived scores highly correlated to upper-
body clinician rated motor symptoms [14]. Whilst extremely 
promising, investigations are now required into how well the 
C3t can predict clinical symptoms to further evaluate its util-
ity as an outcome measure. Additionally, work needs to be 
extended to investigate how well the C3t scores correlate to 
composite clinical scores given the multifaceted presentation 
of HD symptoms. Two notable composite scores requiring 
investigation are i) the composite UHDRS (cUHDRS) which 
is thought to be a stronger global indicator of disease pro-
gression, capturing the changes occurring simultaneously 
across the individual symptom domains in HD [15] and ii) 
the Prognostic Index normed for HD  (PINHD) [16] which has 
been developed to determine projected disease progression.
This study subsequently explored the concurrent and 
convergent validity of the C3t as a simple, objective assess-




Data presented here were drawn from datasets across four 
different studies—PACE-HD, CAPIT-HD2, TRIDENT and 
Developing Clinical Applications for a Novel Multi-Task 
Functional Assessment: The Clinch Token Transfer Test 
(referred to here as NOVELFA-C3T).
PACE-HD (Clinical trials registration: NCT03344601) is 
a multi-center trial with sites in Germany, Spain, and USA, 
where all participants were also concurrently participating in 
Enroll-HD. As PACE-HD is an ongoing intervention study, 
only baseline data were included.
CAPIT-HD2 was a multi-center study with data collected 
across 4 different sites in Europe (Cardiff and Manches-
ter, UK; Créteil Paris, France; Muenster, Germany). In the 
Cardiff, Manchester and Muenster sites, participants were 
recruited from those currently participating in the global 
Enroll-HD study (https ://www.enrol l-hd.org/). In Créteil, par-
ticipants were recruited from those currently enrolled in the 
Predictive Biomarkers for Huntington’s disease study (Clini-
cal trials registration: NCT01412125). Participants completed 
a battery of assessments during a baseline visit and were then 
invited to return for 1-month and 12-month visits to control 
for a retest effect [17]. Data collated at the 1-month time-
point involved a reduced battery of assessments (i.e., did not 
reflect the minimum dataset required for analyses) and was 
thus omitted from the analysis reported here.
TRIDENT and NOVELFA-C3T are both single-site stud-
ies based in Cardiff. Participants were recruited from those 
currently participating in the global Enroll-HD study. They 
were invited to attend a single baseline visit to complete 
the requisite test battery. Ethical approval for all studies 
was granted by Health and Care Research Wales (CAPIT-
HD2 REC: 17/WA/0014, TRIDENT REC: 18/WA/0182, 
NOVELFA-C3T REC: 17/WA/0014).
All participants included in the studies were 18 or more 
years of age, with genetically confirmed HD and the capac-
ity to provide informed consent. Diagnosis of HD was 
categorized into one of four disease stages at each visit 
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(Pre-manifest, Diagnostic Confidence Interval (DCI) ≤ 3; 
Stage 1, Total Functional Capacity (TFC) = 11–13 and 
DCI = 4; Stage 2, TFC = 7–10; Stage 3, TFC = 4–6) [15]. 
The CAG Age Product score (CAP) [18] was calculated 
using age and CAG repeat length to estimate disease impact 
for demographic purposes [19] (Eq. 1).
Assessments and outcome measures
All participants (n = 105) performed the C3t or a prior version 
of the task (Moneybox Test (MBT)) at the baseline visit with 
a subset repeating this at 12 months (n = 33). Both versions 
of the test involve the performance of six (C3t) or five (MTB) 
tasks, with this study focusing on two of the tasks performed 
identically across test versions—the Baseline Transfer Task 
(BTT) and Complex Transfer Task (CTT) which are described 
in full in the C3t manual (Supplementary Material 1). In both 
BTT and CTT tasks, participants picked up a token one at 
a time with their non-dominant hand, transferred it to their 
dominant hand and placed it into a slotted box. During the 
BTT participants transferred eight blank tokens in order of 
physical size (largest to smallest). During the CTT a mild 
cognitive load is added by asking participants to transfer 
a different set of tokens in order of the number printed on 
them (highest to lowest). In both tasks the primary measure 
recorded is the time taken to complete the task (i.e., transfer 
all tokens successfully).
Participants also completed the Unified Huntington’s 
Disease Rating Scale (UHDRS), with scores produced to 
assess the symptom domains of motor function (Total Motor 
Score (TMS)) and cognition (Symbol Digit Modalities Test 
(SDMT) and Stroop Word Reading Test (SWRT)) along 
with capacity (Total Functional Capacity (TFC)). The com-
posite UHDRS (cUHDRS) [15] was used to provide a global 
indicator of HD disease progression (Eq. 2).
Scores on the select UHDRS assessments (TMS, SDMT, 
SWRT, TFC) and the cUHDRS were used as criterion clini-
cal measures to assess the convergent and concurrent valid-
ity of the C3t.
The prognostic index normed for HD  (PINHD) [16] was 
calculated (Eq. 3) to determine projected disease progression 
in the pre-manifest subgroup, with higher scores indicat-
ing greater risk of motor diagnosis. A  PINHD of less than 0 

























indicates greater than 50% 10-year survival, whilst a  PINHD 
of greater than 0 indicated less than 50% 10-year survival.
where
All data were stored in a SQL database using Python 
(v3.7) and subsequently analyzed using SciPy (v1.3.0) [20].
Data analysis
The C3t time taken BTT and CTT scores were assessed for 
normality using multiple statistical tests (Shapiro-Wilks 
Test, D’Agostino K-Squared Test and Anderson–Darling 
Test) and visually inspected using histograms and Q-Q plots. 
Given their non-normal distribution, non-parametric data 
analysis methods were employed.
Least squares regression was performed to determine 
whether HD disease severity, as measured by the UHDRS 
(cUHDRS, TMS, SMDT and SWRT), could be predicted 
using C3t scores (BTT and CTT). The coefficients from a 
LASSO regression (see Supplementary Material 2) con-
firmed that data collected across sites and using the two dif-
ferent versions of the C3t could be pooled as both were found 
to have negligible effects on the regression model. Scatter-
plots of C3t time scores (BTT and CTT) plotted against the 
TMS, SDMT, SWRT and cUHDRS revealed a non-linear 
relationship and as such a polynomial regression (degree of 
2) was performed to optimize the predictive model. The TFC 
was not predicted due to a lack of any discernable pattern 
with the C3t scores (which was confirmed via a scatterplot 
of C3t time scores (BTT and CTT) plotted against TFC). 
The  PINHD was also not predicted due to insufficient sample 
size as this could only be measured for the pre-manifest sub-
group (n = 16). Only data collected during the baseline visit 
were used in the regression models. To ensure robust results, 
repeated k-fold cross-validation was used. Cross-validation 
is a common method used in machine learning to avoid 
overfitting statistical models to datasets, helping to ensure 
robust, generalizable results. K-fold cross-validation splits 
the dataset into k partitions, withholding one partition and 
training/constructing a regression model using the remaining 
k-1 partitions. The quality of the trained regression model 
is then assessed using the withheld partition. This process 
is conducted k times, with each partition taking a turn at 
being withheld and used to assess a regression model trained 
using the remaining k-1 partitions. In repeated k-fold cross-
validation this process is then repeated by randomly shuf-





PIHD = 51 × TMS + (−34) × SDMT + 7 × Age × (CAG − 34)
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internal structure of the original dataset has not, by chance, 
influenced the results of the models.
In this study four folds and ten repeats were used (k = 4, 
repeats = 10), resulting in 40 models constructed overall. 
During each cross-validation fold, the ratio of TFC Stages 
present in the entire dataset was maintained in the training 
and testing sets. The mean absolute error (MAE) and the 
normalized MAE were used to assess model quality for each 
of the 40 models generated during the cross-validation pro-
cess (Eq. 4). The mean MAE and normalized MAE across 
the 40 models are reported. The MAE quantifies on average 
how far off from the actual value (regardless of direction) a 
model is, across a population when predicting a dependent 
variable (in this case the UHDRS scores). The normalized 
MAE was utilized to allow comparison across outcomes 
with varying ranges:
where yi is the actual clinical score, xi is the predicted score 
and n is the sample size.
The strength and direction of association between each 
clinical score and the C3t scores was measured using Spear-
man’s R correlation coefficient. A-priori statistical level of 
significance was set to p ≤0.05.
Scatterplots are reported for each clinical score in rela-
tion to the BTT and CTT scores, with a key denoting disease 
stage for each participant. These were visually inspected to 
evaluate the sensitivity of the C3t to measure clinical impair-
ment across the spectrum of disease state.  PINHD was plot-
ted in a similar manner against the BTT and CTT scores to 
investigate how sensitive the C3t scores may be to overall 
risk of motor diagnosis and probability of 10-year survival. 
With the  PINHD designed to estimate progression levels in 
pre-diagnosis HD, this was only performed on the pre-man-
ifest sub-group.
Baseline to 12-month changes in C3t scores were assessed 
using effect size and compared to clinical scores using data 
from all participants, where follow-up data were available 
(n = 33, with 11 lacking a SWRT score thus reducing sample 
size to 22 when measuring change in SWRT and cUHDRS). 
Effect size was calculated using a nonparametric analog of 
Cohen’s D, omega (Ω), where Ω = 0 indicates no effect and 
values of ± 0.1, ± 0.3 and ± 0.4 correspond to the descriptors 
used for Cohen’s D indicating low, medium and large effect 
sizes, respectively [21]. Unlike Cohen’s D, Ω is directional 
and as such for the sake of simplicity the absolute value of 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































One-hundred-and-five gene-positive participants were 
recruited at the baseline visit across all studies and sites (see 
Table 1, with the number of participants recruited across 
each sub-study and disease stage reported in Supplemen-
tary Material 3). Thirty-three participants also attended the 
12-month follow-up visit.
C3t scores in relation to UHDRS clinical scores
C3t time scores and each of the four UHDRS measures dur-
ing the baseline were highly and significantly associated 
(p < 0.001) with one another (see Table 2) with the strong-
est correlation identified between the cUHDRS and the 
CTT time scores (CTT r = − 0.7). A positive association 
was found between time taken to perform both C3t tasks and 
TMS, where BTT and CTT time increased as TMS score 
increased. In contrast, negative associations were found for 
the cUHDRS, SMDT and SWRT, where time taken to per-
form BTT and CTT increased as clinical scores decreased. 
Scatterplots plotting each clinical score under analysis 
against the BTT and CTT C3t scores are presented in Fig. 1 
to visually represent these associations (with a key denot-
ing disease stage for each participant to aid contextualiza-
tion). No further investigation of relationships between C3t 
and TFC were indicated given the lack of any association 
between C3t scores and the TFC (see Fig. 2).When esti-
mating baseline clinical scores using baseline C3t scores, 
normalized mean absolute error ranged from at best 9% and 
at worst 13% (see Table 2).
C3t scores in relation to predicted 10‑year survival 
rate and motor diagnosis
A positive correlation was found between timed taken to 
perform both C3t tasks and  PINHD in the pre-manifest sub-
group (BTT r = 0.83, p < 0.001; CTT r = 0.76, P < 0.05), 
where BTT and CTT increased as  PINHD score increased 
(see Fig. 3).
Assessing the 12‑month behavior of the C3t
Small changes in C3t scores were reported for baseline to 
12-month changes ( Ω ≤ 0.15) which mirrored the small 
change reported in all clinical scores (see Table 3).
Discussion
The C3t is a quick, easy to administer objective assessment 
that is associated with HD disease status. Previous work 
has shown that the time to perform C3t tasks is related to 
increasing disease manifestation [13]. Here we have re-con-
firmed these findings on a significantly larger cohort with 
representation across a broader spectrum of disease. Addi-
tionally, we have shown that the BTT and CTT task times 
can be used to predict gold-standard motor, cognitive and 
composite clinical measures with a high-degree of accuracy.
In the original development of the C3t, it was proposed 
that the dual task paradigm would elicit motor impairment 
perhaps not seen in simple or single task conditions [22]. 
Yet, it appears that time taken to perform the simple task 
(BTT) and dual task (CTT) are correlated with both motor 
and cognitive clinical outcomes (i.e., increased time to com-
plete the C3t tasks may be as a result of cognitive or motor 
deficits or a combination of both). Whilst it is possible that 
individuals with HD could exhibit differing prioritization 
Table 2  Regression results for C3t scores and clinical measures at baseline
Spearman’s R (** indicates p < 0.001), its corresponding p-value, the Mean Absolute Error (MAE) and Normalised MAE are reported. Spear-
man’s R is calculated across the entire baseline dataset. The MAE and Normalised MAE are the mean results from repeated, k-fold cross-vali-
dated models (k = 4, repeats = 100) stratified across TFC stages. MAE and Normalised MAE results are the mean (± standard deviation) across 
all folds. Cohort max is defined as the maximum value for each clinical measure in the dataset






Baseline transfer task time taken cUHDRS − 0.69** 2.23 (± 0.33) 11.0% (± 2.0%) 19.89
TMS 0.67** 9.88 (± 1.43) 13.0% (± 2.0%) 78
SMDT − 0.63** 8.14 (± 1.08) 11.0% (± 2.0%) 72
SWRT − 0.62** 12.05 (± 1.8) 9.0% (± 1.0%) 134
Complex transfer task time taken cUHDRS − 0.7** 2.11 (± 0.3) 11.0% (± 1.0%) 19.89
TMS 0.69** 9.4 (± 1.18) 12.0% (± 2.0%) 78
SMDT − 0.64** 7.63 (± 1.15) 11.0% (± 2.0%) 72
SWRT − 0.64** 12.02 (± 1.47) 9.0% (± 1.0%) 134
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strategies based on cognitive and motor ability, previous 
studies have found that the majority of participants exhib-
ited mutual interference or prioritized motor over cognitive 
activities [23]. With the BTT and CTT analyses demonstrat-
ing comparable findings, we suggest that there is limited 
added value in performing both the BTT and CTT when 
seeking to estimate global clinical progression using the 
time taken to perform a given task. The utility of each task 
may, however, lie beyond these simple temporal measures 
and requires further investigation.
The notion of multiple domains influencing clinical 
outcomes has been identified by Schobel [15] who recom-
mended the use of a global measure of clinical disease pro-
gression in the cUHDRS given the multifaceted presentation 
of HD. As a composite product of the UHDRS, the cUHDRS 
combines cognitive, motor, and global functional symptom 
domains, and has been found to have enhanced sensitivity to 
clinical change in early symptomatic HD [9]. The C3t timing 
measures were highly associated and predicted the cUHDRS 
to within 11% of the actual score.
C3t scores were found to be associated to  PINHD in pre-
manifest individuals, with a trend for increased time to per-
form the C3t in people with higher  PINHD scores. Thus, it 
appears that the C3t scores are capable of measuring symp-
toms in relation to predicted 10-year survival rate and motor 
diagnosis. This in part would appear to be linked to the role 
that both the TMS and SDMT play in the calculation of 
 PINHD as these scores have independently been found to be 
associated with the C3t. Given the proposed utility of the 
 PINHD to assist the identification of suitable participants into 
HD clinical trials [16], the C3t shows promise as a recruit-
ment screening tool that could lead to improved efficiency 
in clinical trials. With pre-manifest participants representing 
only a relatively small subgroup of the current study cohort, 
further investigation is, however, needed involving a larger 
pre-manifest cohort.
No association between the C3t scores and function as 
measured by TFC was found. TFC is routinely used to define 
the stages of disease severity. It provides a standardized scale 
to assess capacity to work, deal with personal finances, per-
form domestic chores and activities of daily living and self-
care tasks. As such, many factors contribute to functional 
decline that is reflected by TFC scores. In contrast, the C3t 
is designed to primarily assess motor symptoms and has the 
potential to be impacted by cognitive impairment (e.g., psy-
chomotor slowing and attentional deficits). As such, whilst 
some relationship might be expected, the two assessments 
are focused on different measurement domains.
Small changes in C3t scores over a 12-month period 
were in line with those seen in clinical outcomes over the 
same duration. Whilst greater changes in UHDRS over 12 
months have been reported previously [15, 24], progression 
of clinical symptoms can be highly varied within the cohort 
under investigation. The ability to mirror changes in clinical 
outcomes is positive but further investigation is needed to 
ensure this is replicated when larger clinical progression is 
present. Investigations into the short-term stability of the C3t 
when clinical symptoms remain stable is also warranted and 
will be the focus of future work.
A recognized limitation of this study is the under repre-
sentation of later stage and pre-manifest participants. Sur-
prisingly, later stage participants (Stage 3) were younger 
than those in earlier disease stages. We believe this is most 
likely a chance finding given the small numbers of late stage 
participants in our cohort (n = 7). Future work should focus 
on larger sample sizes and in particular the representation of 
both pre-manifest and later stage participants. Larger sample 
sizes per sub-group will allow further analysis to establish 
whether the predictive performance of the C3t is stronger in 
a particular disease stage.
In conclusion, the time taken to perform the C3t tasks is 
associated and reasonably predictive of HD disease status 
as assessed by the UHDRS. Being associated with  PINHD 
in pre-manifest participants, it may also offer utility as a 
screening tool for recruiting onto clinical trials. Further-
more, the C3t scores mirrored the small changes in clini-
cal impairment over 12 months. This study supports the 
potential utility of the C3t to objectively estimate global 
clinical symptom severity in HD. It requires minimal equip-
ment, time, and clinical expertise to perform, thus offering 
a viable solution for remote monitoring of clinical impair-
ment. To facilitate such monitoring, emphasis now needs to 
be placed on streamlining the way in which the C3t can be 
performed in the home setting and how the data is returned 
to the clinical team. With the ability of sensor integration, 
the C3t also facilitates the collection of detailed upper limb 
movement during task performance [14]. Thus, enhancing 
its potential as a sensitive assessment of motor function 
in clinical trials. Given the limited sample size available 
for the longitudinal analysis, future studies should have 
a specific focus on assessing the psychometric properties 
of the C3t over time and across the spectrum of disease 
manifestation.
Fig. 1  Time taken to perform the Baseline Transfer Task (BTT) and 
Complex Transfer Task (CTT) plotted against the Composite Unified 
Huntington’s Disease Rating Scale (cUHDRS), Total Motor Score 
(UHDRS-TMS), Symbol Digit Modalities Test Number Correct 
(SDMT) and Stroop Word Reading Test (SWRT). Participant disease 
stage is denoted by the key
◂
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(TFC) with disease stage of each participant denoted by the key
Fig. 3  Time taken to perform the Baseline Transfer Task (BTT) and Complex Transfer Task (CTT) plotted against Prognostic Index for HD 
 (PINHD) for pre-manifest participants
Table 3  Effect size, Ω, (non-parametric analogue of Cohen’s D) 
results for baseline to 12 months
Due to incomplete data, the sample size for SWRT and cUHDRS 




Baseline Transfer Task (BTT) − 0.060
Complex Transfer Task (CTT) 0.100
Total Motor Score (TMS) − 0.073
Symbol Digit Modalities Test (SDMT) 0.115
Stroop Word Reading Test (SWRT) 0.112
Unified Huntington’s Disease Rating Scale 
(cUHDRS)
0.062
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